[Clinical and laboratory evaluation of efficiency of Helicobacter pylori eradication].
OBJECTIVE
To assess the efficiency of eradication therapy in long-term period using the main signs of functional activity of gastric mucosa (gastrin-17, pepsinogen I, pepsinogen II) and serum antibodies to H. pylori.


METHODS
113 patients with chronic gastritis were examihed using clinical, endoscopic and laboratory-based methods of investigation, including GastroPanel Biohit, Finland.


RESULTS
It was observed that after 12 month of successful eradication therapy the titer of IgG to H. pylori did not exceed 60 IU/l, with pepsinogen I and pepsinogen II cut-off values set under 150 microg/l and 15 microg/l respectively.


CONCLUSIONS
The decrease of the titer of IgG to H. pylori and concentrations of pepsinogen I and II can be used as criteria of successful eradication therapy in long-term period.
Drygina
L B
LB
Poiarkova
N A
NA
Sablin
O A
OA
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D005753:Gastric Mucosa / Q000276:immunology / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D005755:Gastrins / Q000276:immunology / Q000378:metabolism; D016481:Helicobacter Infections / Q000276:immunology / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D020116:Pepsinogen A / Q000276:immunology / Q000378:metabolism; D020115:Pepsinogen C / Q000276:immunology / Q000378:metabolism; D013997:Time Factors
D000907:Antibodies, Bacterial; D005755:Gastrins; D007074:Immunoglobulin G; C013550:gastrin 17; D020115:Pepsinogen C; D020116:Pepsinogen A